Overview Veloxis de Novo Kidney Transplant ECSWD Status: Recruiting Trial end date: 2022-06-30 Target enrollment: Participant gender: Summary This study is designed to evaluate the safety and efficacy of LCPT in combination with rATG, mycophenolate and early corticosteroid withdrawal (CSWD) in de novo kidney transplant recipients. Phase: Phase 4 Details Lead Sponsor: Simon TremblaySimon Tremblay, PharmD, PhDCollaborator: Veloxis PharmaceuticalsTreatments: Antilymphocyte SerumMethylprednisoloneMethylprednisolone acetateMethylprednisolone HemisuccinateMycophenolic AcidPrednisolonePrednisolone acetatePrednisolone hemisuccinatePrednisolone phosphatePrednisoneTacrolimusThymoglobulin